DV
Dividend Vision

NGNE — Neurogene Inc

Neurogene Inc (NGNE)

Total return is -84.9% over the past 12.4 years, 493.9 points behind SPY at 409.0%. Its deepest 1-year drawdown was 52.4%.

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases, with product candidates including NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease, both currently in Phase 1/2 clinical trials. The company does not currently distribute dividends. Neurogene appeals to investors seeking exposure to early-stage genetic medicine development rather than current income.

NGNE key facts

Asset type
Stock
Asset class
Equity
Inception date
03/07/2014
Last close
$36.14
Market cap
$744,944,704
Average volume
115860.0
Beta
1.959
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.54